Cellectar biosciences reports high rate of complete remission in investigator initiated phase i study of iopofosine in combination with external beam radiotherapy in recurrent head and neck cancer

Florham park, n.j., march 04, 2024 (globe newswire) --  cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that iopofosine i 131 in combination with external beam radiation therapy (ebrt) was safe and tolerated in a spore grant supported investigator-initiated phase 1 clinical trial.
CLRB Ratings Summary
CLRB Quant Ranking